ECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logo
  • Home
  • Contact
✕
  • Filter by
  • Categories
  • Tags
  • Authors
  • Show all
  • All
  • Editorials
  • New Trials
  • Ongoing Trials
  • Trial Results
  • All
  • Acute lymphoblastic leukemia
  • Acute myeloid leukemia
  • Adolescents and young adults
  • Advocacy
  • Anal cancer
  • Antioxidants
  • AYA
  • Bladder cancer
  • Blood cancers
  • Brain cancer
  • Breast cancer
  • Cancer care delivery
  • Caregiving
  • Chemotherapy
  • Chronic lymphocytic leukemia
  • Colorectal cancer
  • ComboMATCH
  • Communication
  • COVID-19
  • DCIS
  • DCIS breast cancer
  • De-escalation
  • Esophagus cancer
  • Financial hardship
  • Gallbladder cancer
  • Gastroesophageal cancer
  • Geriatric oncology
  • GI cancer
  • Green tea
  • HAI chemotherapy
  • Head and neck cancer
  • Head and neck squamous cell carcinoma
  • Health equity
  • Hepatic arterial infusion chemotherapy.
  • HER2+ breast cancer
  • Hormone therapy
  • Imaging
  • Immune system therapy
  • Immunotherapy
  • Implementation science
  • In memory
  • Kidney cancer
  • Language
  • Late Effects
  • Leukemia
  • LGBTQ+
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Mammography
  • Mantle cell lymphoma
  • Melanoma
  • Men's health
  • Mesothelioma
  • Minimal residual disease
  • MRI
  • Multiple myeloma
  • Myelodysplastic syndrome
  • Myeloma
  • National Clinical Trials Network
  • NCI-MATCH
  • Neuropathy
  • Non-Hodgkin lymphoma
  • Nose and sinus cancer
  • Older adults
  • Pancreatic cancer
  • Pancreatic cysts
  • Patient care
  • Patient education
  • Patient navigation
  • Patient-reported outcomes
  • Penile cancer
  • Peripheral T-cell lymphoma
  • Personalized medicine
  • Personalized screening
  • Personalized treatment
  • Precision medicine
  • Prevention
  • Prostate cancer
  • Radiation therapy
  • Rare cancer
  • Real-world data
  • Real-world evidence
  • Registry studies
  • Renal cell carcinoma
  • Research results
  • Sarcoma
  • Screening
  • Sexual and gender minorities
  • Side effects
  • Skin cancer
  • Smoldering multiple myeloma
  • Social genomics
  • Soft tissue sarcoma
  • Solid tumors
  • Squamous cell carcinoma
  • Surveillance
  • Survivorship
  • Symptom management
  • Symptom science
  • Targeted therapy
  • Throat cancer
  • Thyroid cancer
  • Triple-negative breast cancer
  • Tumor test
  • Upper tract urothelial cancer
  • Urothelial cancer
  • All
  • Diane Dragaud
  • ECOG-ACRIN Staff
  • Katie Heller
July 19, 2023
July 19, 2023
Categories
  • New Trials

Now Enrolling: The DIRECT study is testing how well FDG-PET/CT imaging can predict if treatment is working prior to surgery for patients with HER2-positive breast cancer

This study is for patients who have untreated, early-stage HER2-positive breast cancer
Do you like it?
0 Read more
July 19, 2023
July 19, 2023
Categories
  • New Trials

Now Enrolling: ComboMATCH treatment trial E4 is testing a new option for patients with advanced solid tumors that progress despite taxane chemotherapy

This study is for patients with solid tumors that are progressing after treatment with taxane therapies
Do you like it?
0 Read more
March 23, 2023
March 23, 2023
Categories
  • New Trials

The ComboMATCH precision medicine initiative is getting set to evaluate several new anti-cancer drug combinations

Hospitals and cancer centers nationwide are opening ComboMATCH on a rolling basis over the next few months
Do you like it?
0 Read more
January 5, 2023
January 5, 2023
Categories
  • New Trials

Now Enrolling: The BRIDGE research study is evaluating a new treatment approach for patients with early bladder cancer

This study is for patients who have aggressive, high-grade tumors that put them at higher risk of recurrence after treatment
Do you like it?
0 Read more
Prev page
123456
Next page

Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2019-2025 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc